TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22839442

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2‐4 g/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Calcitriol (1‐6 g/day orally)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diet (1200‐1800 IU/day of vitamin D with multivitamins and from foodstuffs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo with diet control
Number of subjects: 120
Study: 20421406

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with efavirenz (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with nevirapine (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: lopinavir-ritonavir without NNRTIs (2 tablets [400/100 mg] twice a day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with efavirenz and nevirapine
Number of subjects: 60
Study: 18760888

Group type: EXPERIMENTAL
Intervention: Entertainment-based decision aid for prostate cancer screening
Number of subjects: 450

Group type: COMPARATOR
Intervention: Audiobooklet-control aid
Number of subjects: 450
Study: 16086616

Group type: EXPERIMENTAL
Intervention: Topiramate 300 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12643293

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b plus ribavirin (1,000 to 1,200 mg per day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Interferon-alpha2b plus placebo
Number of subjects: 52
Study: 9350362

Group type: EXPERIMENTAL
Intervention: 2 mg morphine + 100 micrograms fentanyl
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 4 mg morphine + 100 micrograms fentanyl
Number of subjects: 122

Group type: COMPARATOR
Intervention: 2 mg morphine alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: 4 mg morphine alone
Number of subjects: 122
Study: 2022769

Group type: EXPERIMENTAL
Intervention: Material A (soft polymer lining) worn for 14 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Material B (soft polymer lining) worn for 30 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: In vitro tests for both materials A and B
Number of subjects: 10
Study: 6939318

Group type: EXPERIMENTAL
Intervention: Antidepressants (isocarboxazide, lithium citrate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antidepressants (zimelidine, nomifensine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine oxide, mianserin)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antidepressants (maprotiline, nortriptyline, clomipramine, imipramine, amitriptyline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31713697

Group type: EXPERIMENTAL
Intervention: Two miniplates
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: One microplate and one miniplate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (40 healthy adult volunteers)
Number of subjects: 16
Study: 30782865

Group type: EXPERIMENTAL
Intervention: Mindfulness-based and cognitive interventions training, comprising three 4-hour sessions conducted every 2 weeks.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting control group (no intervention initially).
Number of subjects: 96
Study: 29024881

Group type: EXPERIMENTAL
Intervention: Antenatal reflexology (six weekly 30-minute treatments)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual antenatal care only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham (footbath) treatments
Number of subjects: 90
Study: 25943665

Group type: COMPARATOR
Intervention: HEAT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HEAT + CO2
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON
Number of subjects: 8
Study: 24431385

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (160 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 22942337

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 4853

Group type: EXPERIMENTAL
Intervention: β-blocker (BB)
Number of subjects: 4853

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4853

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4853
Study: 19542861

Group type: EXPERIMENTAL
Intervention: Robotic camera holder (RCH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Human camera holder (HCH)
Number of subjects: 44
Study: 17608775

Group type: EXPERIMENTAL
Intervention: First-line treatment with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple regimens for 7-14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential therapy for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPI, levofloxacin, and amoxicillin for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 0
Study: 15455739

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 40
Study: 11596588

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin
Number of subjects: 3351

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole
Number of subjects: 3351

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3351

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin and fluorouracil plus levamisole combined
Number of subjects: 3351

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant therapy
Number of subjects: 3351
Study: 11766711

Group type: EXPERIMENTAL
Intervention: Chinese medicine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sugar water (control)
Number of subjects: 10
Study: 7831045

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 74
Study: 2139916

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 400 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 800 mg/d
Number of subjects: 18
Study: 631536

Group type: EXPERIMENTAL
Intervention: Heparin-Dihydergot (2 x 0.5 mg DHE or 2 x 5000 IU of heparin)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Combination of DHE and heparin
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (3 x 0.5 g)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 454
Study: 31421677

Group type: EXPERIMENTAL
Intervention: Neck extension group (E group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Neutral position group (N group)
Number of subjects: 65
Study: 27939124

Group type: EXPERIMENTAL
Intervention: Low thiamin concentration fish sauce (2 g/L)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: High thiamin concentration fish sauce (8 g/L)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control fish sauce (no thiamin)
Number of subjects: 276
Study: 25923435

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 3.0 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23422472

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 40
Study: 21484393

Group type: EXPERIMENTAL
Intervention: bimanual spring (the objects were connected by a spring)
Number of subjects: 45

Group type: COMPARATOR
Intervention: bimanual no-spring (the objects were not physically connected)
Number of subjects: 45

Group type: COMPARATOR
Intervention: unimanual
Number of subjects: 45
Study: 19534923

Group type: EXPERIMENTAL
Intervention: Dairy product consumption
Number of subjects: 7094

Group type: COMPARATOR
Intervention: Control group (no dairy product consumption)
Number of subjects: 7094
Study: 17711706

Group type: EXPERIMENTAL
Intervention: Intracoronary adenovirus vector encoding hepatocyte growth factor (Ad(5)-HGF 5 x 10(9) pfu) plus stent implantation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Equal physiological saline plus stent implantation
Number of subjects: 18
Study: 15536461

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11550835

Group type: EXPERIMENTAL
Intervention: Autologous fat graft implantation
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no fat graft)
Number of subjects: 186
Study: 9505742

Group type: EXPERIMENTAL
Intervention: 6.5 mm tracheal tube for men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.0 mm tracheal tube for women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.0 and 6.5 mm tracheal tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller size of tube
Number of subjects: 0
Study: 9424863

Group type: EXPERIMENTAL
Intervention: Aneurysms with diameter 3‐4 cm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Aneurysms with diameter 4‐5 cm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Aneurysms with AP diameter bigger than 50 mm
Number of subjects: 86
Study: 2699571

Group type: EXPERIMENTAL
Intervention: Toothpaste A (specific formulation not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothpaste B (specific formulation not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (dentists)
Number of subjects: 0
Study: 1243528

Group type: EXPERIMENTAL
Intervention: Testosterone decanoate plus cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testololactone plus cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drostanolone plus cyclophosphamide
Number of subjects: 0
Study: 30907290

Group type: EXPERIMENTAL
Intervention: Actor condition (animated actor communicating risk information)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static visual formats or paragraph without actor
Number of subjects: 0
Study: 28405611

Group type: EXPERIMENTAL
Intervention: AAV2-GAD gene therapy
Number of subjects: 45
Study: 26298615

Group type: EXPERIMENTAL
Intervention: Intervention: Counseling about etiologic factors and systemic nature of IC
Number of subjects: 19
Study: 23927713

Group type: EXPERIMENTAL
Intervention: D222G variant in ICU patients (n=8/24, 33.3%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: D222N variant in ICU patients (n=8/24, 33.3%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ICU patients with D222G variant
Number of subjects: 24
Study: 22256639

Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Routine complex treatment
Number of subjects: 230
Study: 19332201

Group type: EXPERIMENTAL
Intervention: Occluded culprit artery
Number of subjects: 1957
Study: 16698237

Group type: EXPERIMENTAL
Intervention: Ceftazidime dosage administered by continuous infusion, individualized using a proposed formula based on creatinine clearance and target concentration at steady state.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ceftazidime dosage administered by continuous infusion using the proposed formula.
Number of subjects: 60
Study: 15142066

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (n = 31)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (n = 107/552)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (n = 87/504)
Number of subjects: 66
Study: 11320105

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (two 2.5-mg patches per day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67
Study: 9569785

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine‐containing varnish (Cervitec)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 80
Study: 7970646

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (containing 0.8 mg of folic acid)
Number of subjects: 5502

Group type: COMPARATOR
Intervention: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Number of subjects: 5502
Study: 2835892

Group type: EXPERIMENTAL
Intervention: 6.5 g dietary fibre supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30776393

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study: 29040040

Group type: EXPERIMENTAL
Intervention: Presence of carotid web at the symptomatic side
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Presence of carotid web at the asymptomatic side
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Demographics of patients with symptomatic carotid web
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Risk factors in patients with symptomatic carotid web
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Interobserver agreement in detection of carotid webs
Number of subjects: 443
Study: 27875501

Group type: EXPERIMENTAL
Intervention: Resistance training with ibuprofen (400 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Stretching with placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 90
Study: 25881903

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 459814
Study: 23279217

Group type: EXPERIMENTAL
Intervention: TZP-102 10 mg, 20 mg, 40 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TZP-102 (any dose)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 21639938

Group type: EXPERIMENTAL
Intervention: Educational interventions consisting of a standardized teaching course aimed at doctors and nurses, lasting 6 hours split into three 2-hour blocks with subsequent monthly refresher courses.
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 150000
Study: 18926856

Group type: EXPERIMENTAL
Intervention: Hand movement program (experimental)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Read aloud program (control)
Number of subjects: 61
Study: 16856219

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.0 mg; 1.3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12771597

Group type: EXPERIMENTAL
Intervention: New hub model (Segur-Lock) with antiseptic chamber filled with 3% iodinated alcohol
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard Luer-lock connector (control group)
Number of subjects: 230
Study: 10701059

Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D (treated group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 68
Study: 9377171

Group type: COMPARATOR
Intervention: Recombinant interleukin‐1 receptor antagonist (placebo-controlled)
Number of subjects: 59
Study: 8383943

Group type: EXPERIMENTAL
Intervention: WIN 54954 (600 mg per dose, two doses on the first day followed by three doses on each of the subsequent 5 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: WIN 54954
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3978010

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (200 micrograms fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (50 micrograms fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (100 micrograms fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixtures (all doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixtures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 80
Study: 28990633

Group type: EXPERIMENTAL
Intervention: Exercise training focused on ankle strengthening and mobility, twice per week for 10 weeks.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no exercise program).
Number of subjects: 93
Study: 27107540

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1327
Study: 24584047

Group type: EXPERIMENTAL
Intervention: 5 repetition maximum (5RM) strength exercise bouts
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (no prior strength exercise)
Number of subjects: 11
Study: 22801062

Group type: EXPERIMENTAL
Intervention: Albumin (single intravenous dose at the time of LVP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vasoconstrictor combination of octreotide (20 mg intramuscular injection monthly) and midodrine (10 mg oral, 3 times/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Albumin group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vasoconstrictor group
Number of subjects: 25
Study: 20424399

Group type: EXPERIMENTAL
Intervention: Adherers (n = 38) - patients with an increase >/= 18% in exercise from baseline to 6 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonadherers (n = 33) - patients with no change or an increase in exercise of <18%
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Adherers
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonadherers
Number of subjects: 71
Study: 18761243

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microg/kg followed by 1 mg/kg of propofol
Number of subjects: 199

Group type: COMPARATOR
Intervention: Fentanyl 0.5 microg/kg followed by 1 mg/kg of propofol
Number of subjects: 199
Study: 16227663

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12063371

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin
Number of subjects: 3864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3864

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (among S. aureus carriers)
Number of subjects: 3864

Group type: COMPARATOR
Intervention: Placebo (among S. aureus carriers)
Number of subjects: 3864
Study: 10589634

Group type: EXPERIMENTAL
Intervention: Clonidine-morphine group (oral clonidine 5 microg/kg + epidural morphine 2 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine-morphine group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine-placebo group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo-morphine group
Number of subjects: 60
Study: 8609105

Group type: EXPERIMENTAL
Intervention: Acute primary repair (Group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acute repair with a synthetic ligament-augmentation device (Group 2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acute repair augmented with an autologous bone-patellar ligament-bone graft (Group 3)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group (non-augmented repair)
Number of subjects: 150
Study: 1766054

Group type: EXPERIMENTAL
Intervention: MCT/LCT lipid emulsion
Number of subjects: 18

Group type: COMPARATOR
Intervention: LCT lipid emulsion
Number of subjects: 18
Study: 6870163

Group type: EXPERIMENTAL
Intervention: Layer bandage
Number of subjects: 119

Group type: COMPARATOR
Intervention: Elastic adhesive tape bandage
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Clonixin 300 mg three times daily
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone 100 mg three times daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 30890132

Group type: EXPERIMENTAL
Intervention: Standard care plus multisensory intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 28004335

Group type: EXPERIMENTAL
Intervention: DPP intervention (2-years, telephonic, primary care staff)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Perceived educator support
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Support effect on weight loss
Number of subjects: 257
Study: 27354118

Group type: EXPERIMENTAL
Intervention: QAW039 (500 mg once daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 25117033

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus education (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus strength training (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiotherapy (Control)
Number of subjects: 30
Study: 21779093

Group type: COMPARATOR
Intervention: Low volume (LV) alginate preload (9.9 g alginate in 330 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High volume (HV) alginate preload (15.0 g alginate in 500 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Placebo beverage
Number of subjects: 20
Study: 19616172

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI)‐II
Number of subjects: 9
Study: 17724242

Group type: EXPERIMENTAL
Intervention: Disease management program provided by advanced practice nurses for 8 weeks after discharge
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual care system (Control group)
Number of subjects: 335
Study: 16251566

Group type: EXPERIMENTAL
Intervention: Thermodilution cardiac output (TD-CO)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler cardiac output (ED-CO)
Number of subjects: 58
Study: 12211496

Group type: EXPERIMENTAL
Intervention: Regular dose aspirin (325 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11482124

Group type: EXPERIMENTAL
Intervention: Limited Medicare community care service benefit and case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular medical care (control group)
Number of subjects: 0
Study: 8949670

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI ml‐1 (Visipaque)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iohexol 350 mgI ml‐1 (Omnipaque)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodixanol (60-100 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iohexol (60-100 ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodixanol and Iohexol
Number of subjects: 100